Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients,Affected by Toxicities and Independently Predictive of Virological Response

Hammer S.M. , Squires K.E. , Hughes M.D. , Grimes J.M. , Demeter L.M. , Currier J.S. , Eron J.J. , Feinberg J.E. , Balfour H.H. , Deyton L.R. , Chodakewitz J.A. , & Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immudodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337: 725–733.

Gulick R.M. , Mellors J. W. , Havlir D. , Eron J.J. , Gonzalez C. , McMahon D. , Richman D.D. , Valentine F.T. , Jonas L. , Meibohm A. , Emini E.A. , & Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy. New England Journal of Medicine 1997; 337: 734–739.

Wit FWNM , Van Leeuwen R. , Weverling G.J. , Jurriaans S. , Nauta K. , Steingrover R. , Schuijtemaker J. , Eyssen X. , Fortuin D. , Weeda M. , De Wolf F. , Reiss P. , Danner S.A. , & Lange J.M.A. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. Journal of Infectious Diseases 1999; 179: 790–798.

Ledergerber B. , Egger M. , Opravil M. , Telenti A. , Hirschel B. , Battegay M. , Vernazza P. , Sudre P. , Flepp M. , Furrer H. , Francioli P. , & Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863–868.

Deeks S. , Hecht F.M. , Swanson M. , Elbeik T. , Loftus R. , Cohen P.T. , & Grant R.M. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35–F43.

Haubrich R.H. , Little S.J. , Currier J.S. , Forthal D.N. , Kemper C.A. , Beall G.N. , Johnson D. , Dubé , Hwang J.Y. , & McCutchan J.A. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13: 1099–1107.

Descamps D. , Flandre P. , Calvez V. , Peytavin G. , Meiffredy V. , Collin G. , Delaugerre C. , Robert-Delmas S. , Bazin B. , Aboulker J.P. , Pialoux G. , Raffi F. , & Brun-Vézinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association 2000; 283: 205–211.

Bangsberg D.R. , Hecht F.M. , Charlebois E.D. , Zolopa A.R. , Holodniy M. , Sheiner L. , Bamberger J.D. , Chesney M.A. , & Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357–366.

Lucas G.M. , Chaisson R.E. , & Moore R.D. Highly active anti-retroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 1999; 13: 81–87.

Paterson D.L. , Swindells S. , Mohr J. , Brester M. , Vergis E.N. , Squier C. , Wagener M.M. , & Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000; 133: 21–30.

LeMoing V. , Moatti J.P. , Chene G. , Allioum A. , Brun-Vezinet F. , Meyer L. , Grappin M. , Raffi F. , Leport C. , & Vilde J.L. Early virological response and further virological rebound in a cohort of HIV-infected patients started on protease inhibitors: analysis of predictive factors including a measure of adherence to therapy. Antiviral Therapy 2000; 5 (Suppl. 2): 5.

Catz S.L. , Kelly J.A. , Bogart L.M. , Benotsch E.G. , & McAuliffe T.L. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology 2000; 19: 124–133.

Eldred L.J. , Wu A.W. , Chaisson R.E. , & Moore R.D. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998; 18: 117–125.

Anderson W. , & Weatherburn P. Taking heart? The impact of combination therapy on the lives of people with HIV (Phase 2). 1999. London: Sigma Research.

López-Suárez A. , Fernández-Gutiérrez del Álamo C. , Pérez-Guzmán E. , & Giróron-González J.A. Adherence to the antiretroviral treatment in asymptomatic HIV-infected patients. AIDS 1998; 12: 685–686.

Haynes R.B. , & Dantes R. Determinants of compliance: the disease and the mechanics of treatment. In: Compliance in health care. Edited by Haynes R.B. , Taylor D.W. , & Sackett D.L. 1979; Baltimore: Johns Hopkins University Press.

Gisolf E.H. , Jurriaans S. , Pelgrom J. , Van Wanzeele F. , Van Der Ende M.E. , Brinkman K. , Borst M.J. , De Wolf F. , Japour A.J. , & Danner S.A. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. AIDS 2000; 14: 405–413.

Hugen P.W.H. , Burger D.M. , Aarnoutse R.E. , Baede P. , Nieuwkerk P.T. , & Hekster Y.A. Concentration ratios of protease inhibitors (PIs) can be used to judge non-compliance. First International Workshop on Clinical Pharmacology in HIV Therapy, Noordwijk, the Netherlands, 30 March–1 April 2000. Abstract 3.1.

Nieuwkerk P.T. , Gisolf E.H. , Colebunders R. , Wu A.W. , Danner S.A. , & Sprangers M.A. Quality of life in asymptomatic- and symptomatic patients in a trial of ritonavir/saquinavir therapy. AIDS 2000; 14: 181–187.

Centers for disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 1992; 41: 1–19.

Altman D.G. Practical statistics for medical research. 1991. London: Chapman & Hall.

Hwang J. , Haubrich R. , Currier J. , Forthal D. , Beall G. , Kemper C. , & McCutchan J. Comparison of three statistical measures of HIV RNA suppression in a clinical strategy trial. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 31 January–4 February 1999. Abstract 395.

Moatti J.P. , & Souteyrand Y. HIV/AIDS social and behavioural research: past advances and thoughts about the future. Social Sciences and Medicine 2000; 50: 1519–1532.

Carpenter C.C.J. , Cooper D.A. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Hammer S.M. , Hirsch M.S. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S.G. , Richman D.D. , Saag M.S. , Schechter M. , Schooley R.T. , Thompson M.A. , Vella S. , Yeni P.G. , & Volberding P.A. Antiviral therapy in adults. Updated recommendations of the international AIDS society-USA panel. Journal of the American Medical Association 2000; 283: 381–390.

Gordillo V. , DelAmo J. , Soriano V. , & Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763–1769.